AbbVie Expands Manufacturing Presence in Singapore

February 7, 2014
Melanie Sena

Melanie Sena is community editor of Pharmaceutical Technology.

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-03-05-2014, Volume 10, Issue 3

AbbVie will open its first manufacturing facility in Singapore.

AbbVie

reported a $320 million investment to establish operations in Singapore for small molecule and biologics active drug-substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline.

The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include R&D functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie’s existing presence in Singapore includes 120 employees, supporting commercial operations, global R&D, and general operations.

The investment is expected to result in more than 250 new employees. The new facility is expected to be fully operational by 2019.

Source:

AbbVie

Related Content:

Bio/Pharma Business